Wexford Capital LP Buys Shares of 3,922 Apogee Therapeutics, Inc. (NASDAQ:APGE)

Wexford Capital LP acquired a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,922 shares of the company’s stock, valued at approximately $230,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Apogee Therapeutics during the third quarter worth $71,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apogee Therapeutics by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after purchasing an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Apogee Therapeutics in the second quarter worth $143,000. Arizona State Retirement System boosted its holdings in Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after purchasing an additional 258 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after buying an additional 1,340 shares in the last quarter. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Trading Up 6.0 %

NASDAQ APGE opened at $49.97 on Friday. The business’s 50-day moving average price is $52.41 and its two-hundred day moving average price is $48.31. The firm has a market capitalization of $2.25 billion, a PE ratio of -20.65 and a beta of 2.30. Apogee Therapeutics, Inc. has a 12 month low of $19.91 and a 12 month high of $72.29.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on APGE. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $110.00 target price (up from $95.00) on shares of Apogee Therapeutics in a research note on Tuesday. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Finally, Wedbush increased their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $83.88.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $46.58, for a total transaction of $698,700.00. Following the completion of the sale, the chief executive officer now directly owns 1,324,487 shares in the company, valued at approximately $61,694,604.46. This trade represents a 1.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Carl Dambkowski sold 6,665 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $59.12, for a total value of $394,034.80. Following the completion of the transaction, the insider now directly owns 267,463 shares in the company, valued at $15,812,412.56. This represents a 2.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 89,995 shares of company stock valued at $4,912,264. 36.10% of the stock is currently owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.